Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
7.06
+0.21 (3.07%)
At close: Jun 26, 2026, 4:00 PM EDT
7.08
+0.02 (0.28%)
After-hours: Jun 26, 2026, 5:04 PM EDT
Seres Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Seres Therapeutics stock have an average target of 18, with a low estimate of 12 and a high estimate of 22. The average target predicts an increase of 154.96% from the current stock price of 7.06.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Seres Therapeutics stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Feb '26 | Mar '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 1 | 1 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 3 | 3 | 1 | 1 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Initiates $12 | Buy | Initiates | $12 | +69.97% | Jun 23, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $22 | Buy | Maintains | $22 | +211.61% | May 6, 2026 |
| Piper Sandler | Piper Sandler | Hold Maintains $20 | Hold | Maintains | $20 | +183.29% | Feb 13, 2026 |
Financial Forecast
Revenue This Year
12.86M
from 789.00K
Increased by 1,529.66%
Revenue Next Year
358.00K
from 12.86M
Decreased by -97.22%
EPS This Year
-7.52
from 0.64
EPS Next Year
-6.58
from -7.52
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 25.0M | 716,000 | |
| Avg | 12.9M | 358,000 | |
| Low | 716,000 | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 3,068.6% | -94.4% | |
| Avg | 1,529.7% | -97.2% | |
| Low | -9.3% | -100.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -5.84 | -2.87 | |
| Avg | -7.52 | -6.58 | |
| Low | -9.19 | -10.28 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.